137 related articles for article (PubMed ID: 35325304)
1. Real-world challenges in the management of acute myeloid leukemia: a single-center experience from North India.
Chauhan P; Gupta A; Gopinathan M; Sanjeev ; Garg A; Khanna S; Gupta R; Rahman K; Chandra D; Singh MK; Nityanand S
Ann Hematol; 2022 Jun; 101(6):1261-1273. PubMed ID: 35325304
[TBL] [Abstract][Full Text] [Related]
2. Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy.
Ballo O; Tarazzit I; Stratmann J; Reinheimer C; Hogardt M; Wichelhaus TA; Kempf V; Serve H; Finkelmeier F; Brandts C
PLoS One; 2019; 14(1):e0210991. PubMed ID: 30673776
[TBL] [Abstract][Full Text] [Related]
3. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia.
Tober R; Schnetzke U; Fleischmann M; Yomade O; Schrenk K; Hammersen J; Glaser A; Thiede C; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1569-1583. PubMed ID: 35583829
[TBL] [Abstract][Full Text] [Related]
4. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
5. Febrile neutropenia in patients with acute myeloid leukemia: Outcome in relation to qSOFA score, C-reactive protein, and blood culture findings.
Lappalainen M; Hämäläinen S; Romppanen T; Pulkki K; Pyörälä M; Koivula I; Jantunen E; Juutilainen A
Eur J Haematol; 2020 Dec; 105(6):731-740. PubMed ID: 32740997
[TBL] [Abstract][Full Text] [Related]
6. Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center.
Jain H; Rengaraj K; Sharma V; Bonda A; Chanana R; Thorat J; Ronghe A; Biswas S; Nayak L; Tembhare P; Subramnian P; Shetty D; Patkar N; Bagal B; Sengar M
JCO Glob Oncol; 2020 Nov; 6():1684-1695. PubMed ID: 33156719
[TBL] [Abstract][Full Text] [Related]
7. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia.
Scheich S; Lindner S; Koenig R; Reinheimer C; Wichelhaus TA; Hogardt M; Besier S; Kempf VAJ; Kessel J; Martin H; Wilke AC; Serve H; Bug G; Steffen B
Cancer; 2018 Jan; 124(2):286-296. PubMed ID: 28960264
[TBL] [Abstract][Full Text] [Related]
10. Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia.
Reid JH; Marini BL; Benitez LL; Pettit K; Bixby DL; Burke P; Perissinotti AJ
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):393-400.e1. PubMed ID: 33612433
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world].
Jia JS; Zhu HH; Gong LZ; Zhao T; Wang J; Jiang Q; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):398-403. PubMed ID: 31207705
[No Abstract] [Full Text] [Related]
12. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
[TBL] [Abstract][Full Text] [Related]
13. Factors predicting outcome in high risk febrile neutropenia in patients receiving intensive chemotherapy for acute sleukemia: A prospective, observational study from South India.
Rajendranath R; Balasubramaniyum VK; Vijayakumar V; Ganesan P; Tenali GS
Indian J Cancer; 2014; 51(4):481-6. PubMed ID: 26842171
[TBL] [Abstract][Full Text] [Related]
14. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
[TBL] [Abstract][Full Text] [Related]
15. Pattern of bloodstream infections in patients with hematological malignancies in a tertiary care centre.
Bansal S; Advani SH
Indian J Cancer; 2014; 51(4):447-9. PubMed ID: 26842155
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors in Childhood Acute Myeloid Leukemia; Experience from A Developing Country.
Ghafoor T; Khalil S; Farah T; Ahmed S; Sharif I
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1259. PubMed ID: 33085844
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.
Benicio MTL; Ribeiro AFT; Américo AD; Furtado FM; Glória AB; Lima AS; Santos SM; Xavier SG; Lucena-Araujo AR; Fagundes EM; Rego EM
Leuk Res; 2017 Sep; 60():109-114. PubMed ID: 28777950
[TBL] [Abstract][Full Text] [Related]
18. Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia.
Ciftciler R; Demiroglu H; Haznedaroglu IC; Sayınalp N; Aksu S; Ozcebe O; Goker H; Aydın MS; Buyukasık Y
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):729-734. PubMed ID: 31540855
[TBL] [Abstract][Full Text] [Related]
19. Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015.
Wang CY; Huang HH; Chen HM; Hsiao FY; Ko BS
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e649-e657. PubMed ID: 33931380
[TBL] [Abstract][Full Text] [Related]
20. Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy.
Nedved AN; DeFrates SR; Hladnik LM; Stockerl-Goldstein KE
Pharmacotherapy; 2016 Oct; 36(10):1087-1094. PubMed ID: 27521990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
